PT Lippo Karawaci Tbk (PTLKF)
OTCMKTS
· Delayed Price · Currency is USD
0.0104
+0.0010 (10.64%)
At close: Jan 23, 2025
PT Lippo Karawaci Tbk Revenue
PT Lippo Karawaci Tbk had revenue of 2.02T IDR in the quarter ending March 31, 2025, a decrease of -55.42%. This brings the company's revenue in the last twelve months to 8.84T, down -49.34% year-over-year. In the year 2024, PT Lippo Karawaci Tbk had annual revenue of 11.35T, down -32.06%.
Revenue (ttm)
8,837.51B IDR
Revenue Growth
-49.34%
P/S Ratio
0.69
Revenue / Employee
5.17B IDR
Employees
1,708
Market Cap
365.91M USD
Revenue Chart
* This company reports financials in IDR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11.35T | -5,354.06B | -32.06% |
Dec 31, 2023 | 16.70T | 2,027.95B | 13.82% |
Dec 31, 2022 | 14.67T | -1,464.45B | -9.07% |
Dec 31, 2021 | 16.14T | 4,327.58B | 36.64% |
Dec 31, 2020 | 11.81T | -366.22B | -3.01% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Elite Pharmaceuticals | 70.00M |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Northwest Biotherapeutics | 1.47M |
Glass House Brands | 215.62M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |